For pharma & clinical trial sponsors
Add reproducible, sensitive psychophysiological endpoints to your trial. BioXR delivers standardised VR stimuli with synchronised biometric capture, so treatment effects don't have to be inferred from rating scales alone.
Psychiatric and CNS trials have some of the lowest success rates in pharma. Patient-reported outcomes and clinician-administered scales are inherently noisy: rater drift, placebo response, and patient heterogeneity compound across visits, masking real treatment effects and inflating sample sizes.
Adding an objective, physiology-based endpoint changes that picture. A standardised provocation in VR, paired with continuous biometric capture, produces a within-subject signal that is reproducible across sites, sensitive to pharmacological change, and traceable from raw sensor data to final readout.
Scenarios authored by our in-house psychology and psychiatry team and optimised for impact, then delivered identically to every participant across sites and visits. No rater drift, no site-level paradigm differences, no rescue analyses for stimulus inconsistency.
HRV, EDA, respiration, eye-tracking and pupillometry, all time-locked to scenario events. Multi-modal endpoints with millisecond alignment, ready for endpoint adjudication.
Encrypted storage, role-based access, and full provenance from raw signal to processed endpoint. Suitable for early-phase exploratory work today; independent ethical review is still required, and broader regulatory certifications (ISO 13485, 21 CFR Part 11) are on the roadmap.